Our History
2020
Following the emergence of the COVID-19 pandemic at the beginning of 2020, our activities were adapted to the new "normal". Like so many other companies, our employees across Europe were either in lockdown and working from home, or back at their offices depending on the situation.
tebu-bio's headquarters (France) and local offices across Europe, continued to organise purchasing, deliveries and technical support, in accordance with official restrictions and recommendations per country. Our laboratories maintained all ongoing projects and initiated new services in response to customer demand.
Throughout, we provided the research community with new tools to fight the pandemic and to accelerate their research on all fronts. tebu-bio's long-standing partnership with TriLink, pioneers in mRNA development, as well as other renowned brands, enabled us to respond quickly and to supply the reagents and services that scientists are continuously seeking.
2019

To start off the year, we validated our ISO9001:2015 and ISO14001:2015 accreditation. We recently attended the annual AACR Meeting in Atlanta, where Julien Duez PhD (Project Manager at tebu-bio's labs) presented another poster entitled "Standardized 3D spheroid systems facilitate drug screening and biomarker identification with high relevance for cancer drug discovery". In this study, we show the effects of CDK8 inhibitors on a panel of biomarkers analysed through multiplex arrays, comparing 2D culture of colorectal cancer cells to 3D cultures in hypoxia and pro-inflammatory conditions. This work illustrates the services we currently offer combining cell culture and biomarker discovery.
We are also pleased to renew our membership with the AFSSI (l'Association Française des Sociétés de Services et d'Innovation - Sciences de la Vie), the French Association of Companies in Services & Innovation in Life Sciences.
As part of our ISO14001 actions in favour of our environment, we have allocated part of our grounds at our headquarters at Le Perray en Yvelines (France), to become a wildflower garden, and local beekeepers have installed hives. We look forward to tasting the honey that will be produced!
2018
This year, we've attended a number of meetings, presenting results of work performed in our labs. Beginning in January, we presented a poster at the ESACT 2018 meeting in the UK on the topic "Development of advanced 3D culture models to evaluate cellular responses". In April, we attended the AACR meeting in Chicago, presenting a poster entitled "Time-lapse analysis of drug response and invasive capacity using patient-derived CRC microfluidic 3D cancer models under oxygen controlled conditions". Another poster was presented at the DECHEMA 3D Cell culture meeting, on the topic "Advanced physiologically-relevant 3D models for pre-clinical screening". These posters show different aspects of our CellPhy offer, for physiologically relevant conditions.
In May, Isabelle Topin presented a poster "More and Better - Innovative tips and tricks for production and purification of unstable proteins" at the SBCN2018 meeting in Bordeaux, based on her experience as Project Manager of the protein production and purification platform at tebu-bio's laboratories.
In November, Joost Boex (Key Account Manager - tebu-bio Netherlands) attended the Dutch Biophysics meeting, where he presented a poster on "SiR probes - a simple way to decipher complex 3D cell culture models" demonstrating the high efficiency of the SiR probes for Live Cell Imaging.
2017
We are pleased to launch a new service for 3D cell culture spheroid production, recreating the 3D environment seen in the body, thus permitting complex in vitro cell / tissue interactions thus mimicking in vivo environments.
tebu-bio again this year presented a poster at the AACR meeting in Washington, DC (USA). Nadia Normand Ph.D, Business Development Manager at tebu-bio, presented our abstract produced in collaboration with the CNRS (France), Anaxomics (Spain) and the Institute of Immunology and Experimental Therapy (Poland) :
"miRNome analyses reveal that activity of CAF expressed podoplanin in the tumour microenvironment is modulated by exosome miRNAs involved in PTEN/PI3K/AKT/mTOR signalling"
tebu-bio's CIR accreditation is again renewed for a further three years (2017, 2018 & 2019), enabling private French companies to benefit from tax refunds on their expenses for R&D performed by tebu-bio's own European laboratories based near Paris. We initially obtained this accreditation in 2008, which has subsequently been renewed each time.
2016
2015

- Comparison of different highly sensitive miRNA array platforms for the investigation of circulating cell-free microRNAs in blood
- Cytokine profiling of drug-disrupted tumor cell/fibroblast crosstalk provides insights to understand the protective role of the stroma in collaboration with the Institut Català d'Oncologia.
2014




tebu-bio launches a series of new e-Newsletters and a blog named "Being bio-reactive", aimed at informing and sharing news in Life Sciences and Biotechnologies.
2013

tebu-bio and tebu-bio Laboratories merge to form a single company, to more efficiently provide reagents & services to researchers across Europe.
2012
.png)

Among the new brands: Quansys Biosciences, Sunred Biological Technology, EnoGene Biotech, Assay Biotechnology, MUbio, Biosensis, Osenses, Full Moon Biosystems...
2011
tebu-bio Laboratories receive official renewal of their CIR (Crédit d'Impôt sur la Recherche) accreditation.
2010
2009
2008
2007
2006
2005
2004
tebu-bio APS is opened in Denmark, covering all Nordic territories.
2003
A new unified name is chosen for the group, tebu-bio. SPB is renamed to tebu-bio laboratories.
A shadow is added to the logo.
2001
Premises at Le Perray are extended to include larger offices for technical sales staff, IT, accounting…
The whole of the original building is dedicated to a new Logistics department.
Based in Paris, the new company promotes and sells products manufactured by the Dutch plant.